Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...

London, UK-based Cytospire said this morning that it has raked in £61 million ($83 million) in the round, which will fund its ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the American Association for Cancer ...

Cytospire Therapeutics has secured $83 million in Series A funding to progress its first-in-class pan-gamma delta T cell engagers into clinical trials for cancer. The approach aims to overcome safety ...

FDA fast track designation enables increased regulatory interaction and potential rolling BLA review for RPTR-1.201 in ...

Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer Tumor tissue from 868 patients in the QUASAR ...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of ...

UCB, a global biopharmaceutical company, today announced signing of a definitive agreement under which it would acquire ...

Comparison of primary versus metastatic tumor tissue sources when designing panels for whole genome–based tumor-informed ctDNA assays in clear cell renal cell carcinoma. Association of KRAS G12D vs.

UCB has agreed to acquire Candid Therapeutics for up-to-$2.2 billion, in a deal designed to expand the buyer’s presence in ...